Rebecca J. Jaslow, MD
Departments
Cooper University Health Care Titles
- Director, William G. Rohrer Cancer Genetics Program
- Hematologist/Medical Oncologist
Board Certifications
- American Board of Internal Medicine (Medical Oncology)
Professional Type
Cooper University Physician
NPI
1992774996
Office Locations
MD Anderson Cancer Center at Cooper - Camden
Two Cooper Plaza
Camden
, NJ 08103
Phone: 855.MDA.COOPER (855.632.2667)
Maps
& Directions
MD Anderson Cancer Center at Cooper - Voorhees
900 Centennial Boulevard
Building 1
Suite F
Voorhees
, NJ 08043
Phone: 855.MDA.COOPER (855.632.2667)
Fax: 856.325.6645
Maps
& Directions
Cooper University Health Care Moorestown Campus
400 NJ-38
Moorestown Mall
Moorestown
, NJ 08057
Phone: 855.632.2667
Maps
& Directions
Education & Training
| Medical School | Mount Sinai School of Medicine, New York, NY |
|---|---|
| Internship | Internal Medicine - Mount Sinai Hospital, New York, NY |
| Residency | Internal Medicine - Mount Sinai Hospital, New York, NY |
| Fellowship | Hematology and Oncology - New York Presbyterian Hospital/Weill Cornell Medical Center, New York, NY |
Memberships
- American Society of Clinical Oncology
Publications
Wang C, Mu Z, Ye Z, Zhang Z, Abu-Khalaf MM, Silver DP, Palazzo JP, Jagannathan G, Fellin FM, Bhattacharya S, Jaslow RJ, Tsangaris TN, Berger A, Neupane M, Cescon TP, Lopez A, Yao K, Chong W, Lu B, Myers RE, Hou L, Wei Q, Li B, Cristofanilli M, Yang H. Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors. Breast Cancer Res Treat. 2020 Jun;181(3):679-689. doi: 10.1007/s10549-020-05662-x. Epub 2020 May 4. PMID: 32367460; PMCID: PMC7299127.
Laufer T, Lerner B, Petrich A, Quinn AM, Ernst L, Roop A, Knoblauch J, Leasure NC, Jaslow RJ, Hegarty S, Leader A, Barsevick A. Evaluation of a Technology-Based Survivor Care Plan for Breast Cancer Survivors: Pre-Post Pilot Study. JMIR Cancer. 2019 Dec 20;5(2):e12090. doi: 10.2196/12090. PMID: 31859683; PMCID: PMC6942181.
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5. PMID: 30516102.
Ye Z, Wang C, Wan S, Mu Z, Zhang Z, Abu-Khalaf MM, Fellin FM, Silver DP, Neupane M, Jaslow RJ, Bhattacharya S, Tsangaris TN, Chervoneva I, Berger A, Austin L, Palazzo JP, Myers RE, Pancholy N, Toorkey D, Yao K, Krall M, Li X, Chen X, Fu X, Xing J, Hou L, Wei Q, Li B, Cristofanilli M, Yang H. Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA. Eur J Cancer. 2019 Jan;106:133-143. doi: 10.1016/j.ejca.2018.10.012. Epub 2018 Dec 4. PMID: 30528798; PMCID: PMC6347110.
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13. PMID: 29146401.